Format

Send to

Choose Destination
Lung Cancer. 2017 Jul;109:137-144. doi: 10.1016/j.lungcan.2017.04.016. Epub 2017 Apr 27.

Uncommon EGFR mutations in advanced non-small cell lung cancer.

Author information

1
Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON M5G 2M9, Canada. Electronic address: okaneg@tcd.ie.
2
Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON M5G 2M9, Canada.

Abstract

Molecular profiling in advanced non-small cell lung cancer (NSCLC) has allowed for the detection of actionable mutations, which has revolutionized the treatment paradigm in this highly fatal disease. Mutations involving the epidermal growth factor receptor (EGFR) gene are most common and the 'classical mutations', exon 19 deletions and the point mutation L858R at exon 21, predict response to EGFR tyrosine kinase inhibitors (TKIs). The 'uncommon' EGFR mutations account for 10-18% of all EGFR mutations and primarily consist of exon 20 insertions, exon 18 point mutations and complex mutations. Improved detection techniques have broadened the spectrum of reported aberrations within the 'uncommon group' but response to TKIs is variable and not fully elucidated. This review provides an overview of the biology and incidence of uncommon EGFR mutations and summarizes reported outcomes when treated with EGFR-TKIs.

KEYWORDS:

EGFR mutations; NSCLC; Tyrosine kinase inhibitors; Uncommon

PMID:
28577943
DOI:
10.1016/j.lungcan.2017.04.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center